We have multiple roles available. Please read below about the positions we are recruiting for, when you apply you will be able to select 3 preferences. We will accommodate your preference where possible.
The Functional Genomics (FxG) department comprises several disciplines that provide the deep scientific knowledge and technical capabilities required to discover and validate potential novel therapeutic targets through the application of extensive genetic analyses, high throughput genome editing and endophenotyping in well-characterized human cellular models.
We have exciting opportunities for industrial placement students to join the Genome Biology and Omics Technologies groups within the Functional Genomics Department. Students would be primarily aligned to one of the key areas; although opportunities for cross-disciplinary training may be expected as required by role.
The Product Development & Supply team is responsible for developing and manufacturing cutting edge medicines through gene modification of patient cells from early phase to launch, and the development of innovative technologies to enable step-change improvements to cell and gene therapy (CGT) manufacture.
You will be involved in the development of CGT platform technologies and participate in activities related to the understanding and improvement of the medicines that we produce. You will be responsible for developing and applying high quality science, alongside recording and communicating experimental results. You will also be expected to actively contribute to team culture and the day to day running of the laboratory and projects.
The Synthetic Biochemistry group is an enterprise group within the Cell and Gene Therapy department, supporting several business areas within R&D and Pharma Supply Chain. Our group’s mission is to develop and deliver enzymes as biocatalysts, for tools in the synthesis of small molecule APIs (active pharmaceutical ingredients). Using biocatalysts in the synthesis of APIs can offer many advantages over traditional synthetic processes – including increased selectivity and reduced environmental impact.
The group employs a range of state of the art biochemistry, molecular biology and analytical techniques to identify and engineer enzymes for this purpose. A successful candidate will work with a range of these techniques and will have the opportunity to contribute to enzyme panel builds, using molecular biology techniques to clone enzyme candidates, develop and optimise expression of recombinant enzymes on a variety of scales, and develop assays to assess the activity of enzymes using UPLC/GC. Many of these tasks will involve the use of automation to facilitate high-throughput experimentation.
The Novel Human Genetics Research Unit based at the Stevenage research and development hub is comprised of a multidisciplinary team of passionate scientists striving to develop novel medications for some of the world’s most pressing diseases. We utilise expansive genetic data sets to direct our studies and progression points with the knowledge that having genetically validated drug targets increases the chance of success in the clinic and ultimately in delivering medicines to the patients that need them.
The unit is responsible for progressing drug discovery programmes from target identification all the way through to Phase I clinical trials; incorporating target validation, lead discovery, lead optimisation, pharmacokinetics and biomarker strategy.
Biopharm Process Research: BPR is dedicated to de-risking and accelerating GSKs portfolio of biopharmaceuticals from Discovery Research into Clinical Manufacture. By applying state of the art bioprocessing technology, BPR screens candidate molecules for ‘manufacturability’ and quality prior to transfer to late-stage development & clinical manufacturing.
As part of our continuous improvement of our manufacturing platform, the successful students will be deployed across the department to evaluate and embed new technologies or data solutions to improve our ways of working and our scientific output.
Adoptive cell therapy aims to treat cancer patients with modified immune cells that infiltrate tumour tissue and specifically kill the tumour cells. The Oncology Cell Therapy (OCT) Research Unit is responsible for cell therapy programmes at an early stage of drug discovery, evaluating new tumour cell targets and generating novel approaches to enhance efficacy in patients with solid tumours.
Our unit comprises scientists from a range of scientific backgrounds and experience, and we have successfully hosted many students. You will become an active member of the Unit and your work will directly support ongoing programmes.
GSK are a science-led global healthcare company that researches and develops innovative Pharmaceuticals and Vaccines products. Our challenging and inspiring mission is to enable people to do more, feel better and live longer by developing innovative products and improving access to healthcare for patients around the world.
To apply for this role and to find out more, please click on the apply button below.
Please note that applications may close before the application deadline, so apply early to avoid disappointment.